Friday, September 22, 2023
Immunotherapy Collaborative of Networked Communities (IC ONC) is an initiative designed to educate oncologists and the cancer team on advances in cancer immunotherapy.
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC collaborators include the following professional societies,
educational providers and outcomes partners:
In partnership with
Supported by an educational grant from
Bristol-Myers Squibb
IC-ONC has been designed to build local communities that serve as the foundation of a global network in which multidisciplinary clinicians responsible for treating patients with cancer are connected via education. Resources curated by both national and local oncology experts are made available to facilitate ongoing communication and collaboration among participating clinicians with the aim of providing optimal care for the patient.
Experts Adil Daud, MD, Jose Lutzky, MD, and Peter Schmid, MD, PhD, FRCP. Recent trials in immunotherapy have changed the approach to treatment of solid tumors.
Download
Experts Arjun V. Balar, MD, Jason Luke, MD, FACP, and Jeffrey S. Weber, MD, PhD. Recent trials in immunotherapy have changed the approach to treatment of solid tumors.
Download
Experts Adil Daud, MD, Jose Lutzky, MD, and Peter Schmid, MD, PhD, FRCP. Recent trials in immunotherapy have changed the approach to treatment of solid tumors.
Download
Experts Farah Louise Lim, MD and Peter Schmid, MD, PhD, FRCP. Recent trials in immunotherapy have changed the approach to treatment of solid tumors.
Download
Review the latest insights into the use of immunotherapy in squamous cell head and neck cancer.
Download
Animation 1: Cancer and the Immune System
Animation 2: Immune Checkpoint Blockade: PD-1_PD-L1_CIT_PD1
Coming Soon
As part of our multi-year project we will perform some innovative observational outcomes studies, looking at the impact of our educational programs and community participation in improving patient outcomes.
If you would like to participate in our Observatory, please send an email to [email protected] to request additional information or to be enrolled in this exciting project.
Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Medical Center, New York, NY
Assistant Professor of Medicine; Director-Genitourinary Medical Oncology Program, NYU Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY
Professor, Department of Genitourinary Medical Oncology; Professor, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Centre Lead, Centre for Experimental Cancer Medicine, Director, Breast Cancer, St Bartholomew Hospital, London, UK
Department of Hematology and Oncology, Associate Director, Center for Immuno-Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
HS Clinical Professor, Department of Medicine (Hematology/Oncology); USCF Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Associate Professor, David Geffen School of Medicine at UCLA, Los Angeles, CA
Assistant Professor of Medicine, The University of Chicago Medicine, Chicago, IL
Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
Chief, Division of Hematology & Oncology; Chair, Cancer Research Committee; Director, Mount Sinai Melanoma Program, Miami Beach, FL
Barts Cancer Institute Centre for Experimental Cancer Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London
Has disclosed the following relevant financial relationships:
Has received consulting fees from BMS, Merck, Incyte, Genentech, GlaxoSmithKline, AstraZeneca, EMD Serono, and Novartis.
Has stock/stock options with Celldux, Alton, and Cytomx.
Named on a patent for a PD-1 biomarker by Biodesix.
Has disclosed the following relevant financial relationships:
Has an Advisory/Consultancy Role and Honoraria with AstraZeneca/Medimmune; Genentech, Inc./F. Hoffmann La Roche Ltd.; Merck & Co., Inc., and Pfizer.
Has performed contracted research for Merck & Co., Inc.
Has received grant support from Genentech. Inc. / F. Hofmann-La Roche Ltd. and Merck & Co Inc.
Has disclosed no relevant financial relationships.
Has disclosed no relevant financial relationships.
Has disclosed no relevant financial relationships.
Has disclosed no relevant financial relationships.
Has disclosed no relevant financial relationships.
Has disclosed the following relevant financial relationships:
Received consultant fees from 7 Hills, Actym, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Janssen, Merck, NewLink, Nimbus, Novartis, Palleon, RefleXion, Syndax, Tempest; and has received clinical trial support to an institution from AbbVie, Boston Biomedical, Bristol-Myers Squibb, Celldex, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, Intensity, MedImmune, Macrogenics, Novartis, Pharmacyclics, Merck, and Tesaro.
Has disclosed no relevant financial relationships.
Has disclosed the following relevant financial relationships:
eceived consultant fees from Bristol-Myers Squibb; and has served on the speakers' bureau for Bristol-Myers Squibb, and Novartis.
Has disclosed no relevant financial relationships.
Ask the Experts
What are your questions and comments on the use of immune checkpoint inhibition in the treatment of cancer?
Join the Discussion